PUMA
16.5.2023 15:41:29 CEST | Business Wire | Press release
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005712/en/
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA. (Photo: Business Wire)
Ever worn white or tight sports uniforms that made you feel uncomfortable about leaking when playing on your period? Or felt exposed in sportswear that left the wings and strings of your disposables on display?
From archaic sports codes to national team uniform fines, athletes are often told to keep playing on their period, when what they’re told to wear makes it extremely uncomfortable and anxiety-inducing.
But that’s about to change. Enter PUMA x Modibodi active period underwear. The new PUMA x Modibodi active period underwear is in league of its own – made for maximum protection and performance on and off the court, field or gym floor. The collection combines soft, breathable fabrics that stretch and move with your body with Modibodi’s concealed absorbent lining, proven to keep you free from leaks, sweat and discharge.
Modibodi Ambassador and Brisbane City FC Captain, Jamilla Riley, says: “As someone who menstruates and plays soccer in a white uniform, I can attest to the discomfort and anxiety that combination can create, particularly when you are young. You spend your time shamed by the fear of leaks, and it can take all your mental strength to refocus on the game at hand. That’s why I’m such an advocate of the new PUMA x Modibodi active period undies. The designs not only bring some much-needed innovation to the sportswear market, but they also help support your menstruating body so you can play without fear of leaking and kick some goals. Who knew playing on your period could be this comfy It’s liberating!”
Modibodi Design and Innovation Director, Charissa Lanham says: “We wanted to destigmatise the challenges of menstruating whilst competing and show athletes a new world in which they can feel confident and supported to play while they bleed. We worked with PUMA to design a range of active period underwear that utilises Modibodi’s world-first patented technology which includes a leak-proof barrier layer for secure protection; meaning athletes can focus on their game, not their period.”
A workout staple, the PUMA x Modibodi collection absorbs fast and offers peace of mind on the pitch by replacing the need for disposable pads, liners and tampons as you play. The super slim, absorbent black lining is designed to help prevent leaks and unwanted stains. Featuring 3 layers of built-in technology that can hold up to 15ml (or 2-3 tampons) without staining your activewear or sports uniform.
To ensure comfort, each design is crafted from 82% recycled material, includes a wider logo waist band for security whilst playing and an aerated mesh side panel to maximise airflow. Modibodi’s proprietary Modifier Technology™ then works to wick moisture and sweat, locking away fluid and odour to keep you feeling fresh and dry.
Available in a two-colour ways Black/Platinum Grey and Black/Green, the collection consists of 3 styles in a range of Light-Moderate to Moderate-Heavy absorbencies, making them ideal to absorb your period and sweat, and keep you fresh and dry, way beyond the final whistle.
The PUMA x Modibodi collection is available online at modibodi.com.
The PUMA x Modibodi collection is available in selected stores and online at puma.com and modibodi.com.
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
MODIBODI |
Since 2013, Modibodi® has had one goal – to make changing the world as easy as changing your underwear. What they didn’t realise, is that in doing so, they’d change the lives of their customers along the way.
Life-changing is the number one phrase heard from Modibodi customers. It’s a language woven into the brand’s DNA and sits firmly at the heart of what they do. Having made a name for itself globally, designing confidence-shaping, confidence-creating, planet-sustaining, life-changing apparel, Modibodi® offers comfort from periods, pee and bodily leaks, and champions conversations and initiatives that allow people to live more comfortably in themselves.
Designed with compassion and offering a sustainable solution to disposable products, Modibodi uses proprietary innovation and patented technology to ensure each and every one of their designs is market leading, saving billions of single-use disposable hygiene products from ending up in landfill.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
